AbbVie Inc (ABBV – Q1FY20) – HUMIRA, SKYRIZI and RINVOQ played crucial role in revenue growth.

in , on July 21, 2020

AbbVie and Genmab will work together on three prospective antibody products, as well as potential antibody cancer therapies. AbbVie paid $750mn to Genmab right out of the gate, with additional instalments of up to $3.15bn to follow.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q1FY20 – Results
– Q1FY20 – Product Revenue
– Q1FY20 – R&D Update
– FY20 Guidance
– Conclusion
– GAAP to Non-GAAP reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Balance Sheet and Cash Flow ratios
– P/E Band

Product Performance and Key Developments

–Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

 CrispIdea Coverage Chart

Release Information

  • Released
    :

    July 21, 2020

  • Last Updated
    :

    July 21, 2020